Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 12/20 | 1.00 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.66 |
| ▸ | AHCYL1 | O43865 | 1/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.56 |
| ▸ | DPP4 | P27487 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.56 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.56 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.56 |
| ▸ | GAPDH | P04406 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.56 |
| ▸ | STAT6 | P42226 | 1/20 | 0.56 |
| ▸ | PI4KA | P42356 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.56 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Neoplanocin A SCHEMBL863873 | 1.00 | AHCY (1.00) | AHCYEZH2AHCYL1ADORA3DPP4 | |
| Neoplanocin A SCHEMBL30001474 | 1.00 | AHCY (1.00) | AHCYEZH2AHCYL1ADORA3DPP4 | |
| Neoplanocin A SCHEMBL12174034 | 1.00 | AHCY (1.00) | AHCYEZH2AHCYL1ADORA3DPP4 | |
| Neoplanocin A SCHEMBL30543748 | 1.00 | AHCY (1.00) | AHCYEZH2AHCYL1ADORA3DPP4 | |
| Neoplanocin A SCHEMBL29708080 | 1.00 | AHCY (1.00) | AHCYEZH2AHCYL1ADORA3DPP4 | |
| Neoplanocin A SCHEMBL17117192 | 1.00 | AHCY (1.00) | AHCYEZH2AHCYL1ADORA3DPP4 | |
| Neoplanocin A SCHEMBL12157269 | 1.00 | AHCY (1.00) | AHCYEZH2AHCYL1ADORA3DPP4 | |
| Neoplanocin A SCHEMBL10576831 | 1.00 | AHCY (1.00) | AHCYEZH2AHCYL1ADORA3DPP4 | |
| SCHEMBL15396253 | 0.90 | AHCY (1.00) | AHCYEZH2AHCYL1ADORA3DPP4 | |
| SCHEMBL29711226 | 0.90 | AHCY (1.00) | AHCYEZH2AHCYL1ADORA3DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340848-A1 | METHODS FOR CHEMICAL REPROGRAMMING AND PLURIPOTENT STEM CELLS | PEKING UNIVERSITY (CN) | 2025-11-06 | — | — | US | claimed |
| CN-120127338-A | Diaphragm modified material and preparation method thereof, modified diaphragm and preparation method thereof | 西南石油大学 | 2025-06-10 | — | — | CN | claimed |
| EP-3019596-B1 | COMPOSITIONS AND METHODS FOR REPROGRAMING NON- PLURIPOTENT CELLS INTO PLURIPOTENT STEM CELLS | HONG GUAN LTD (CN) | 2023-07-05 | — | — | EP | claimed |
| WO-2022160323-A1 | APPLICATION OF NUCLEOSIDE ANALOGUE IN PREPARATION OF DRUGS FOR PREVENTING OR TREATING GASTROINTESTINAL DISEASES | 兰州大学 | 2022-08-04 | — | — | WO | claimed |
| CN-114533739-A | Application of nucleoside analogue in preparing medicine for preventing or treating gastrointestinal tract diseases | 兰州大学 | 2022-05-27 | — | — | CN | claimed |
| US-12590288-B2 | Method of treating an inflammatory disease by administering an agent which binds a surface receptor on a tuft cell that induces an ILC class 2 inflammatory response | THE BROAD INSTITUTE, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-12466849-B2 | Anti-viral and anti-tumoral compounds | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2025-11-11 | — | — | US | disclosed |
| US-20250340848-A1 | METHODS FOR CHEMICAL REPROGRAMMING AND PLURIPOTENT STEM CELLS | PEKING UNIVERSITY (CN) | 2025-11-06 | — | — | US | disclosed |
| US-20250326725-A1 | PI4-Kinase Inhibitors and Methods of Using the Same | UNIV LELAND STANFORD JUNIOR (US) | 2025-10-23 | — | — | US | disclosed |
| US-12415788-B2 | PI4-kinase inhibitors and methods of using the same | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-09-16 | — | — | US | disclosed |
| EP-4602148-A1 | METHODS FOR CHEMICAL REPROGRAMMING AND PLURIPOTENT STEM CELLS | Peking University (CN) | 2025-08-20 | — | — | EP | disclosed |
| CN-120127338-A | Diaphragm modified material and preparation method thereof, modified diaphragm and preparation method thereof | 西南石油大学 | 2025-06-10 | — | — | CN | disclosed |
| US-20150291640-A1 | PHOSPHONUCLEOSIDES USEFUL IN THE TREATMENT OF VIRAL DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2015-10-15 | — | — | US | disclosed |
| US-20150291640-A1 | PHOSPHONUCLEOSIDES USEFUL IN THE TREATMENT OF VIRAL DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2015-10-15 | — | — | US | disclosed |
| WO-2014204856-A1 | FATTY ACID ANTICANCER DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2014-12-24 | — | — | WO | disclosed |
| WO-2014079903-A1 | PHOSPHONUCLEOSIDES USEFUL IN THE TREATMENT OF VIRAL DISORDERS | UNIVERSITY COLLEGE CORK (IE) | 2014-05-30 | — | — | WO | disclosed |
| US-20110237606-A1 | 3-Deazaneplanocin Derivatives | AGENCY OF SCIENCE, TECHNOLOGY AND RESEARCH | 2011-09-29 | — | — | US | disclosed |
| US-20110237606-A1 | 3-Deazaneplanocin Derivatives | AGENCY OF SCIENCE, TECHNOLOGY AND RESEARCH | 2011-09-29 | — | — | US | disclosed |
| WO-2010036213-A1 | 3-DEAZANEPLANOCIN DERIVATIVES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2010-04-01 | — | — | WO | disclosed |
| US-4968690-A | 3-deazaneplanocin, intermediates for it, and antiviral composition and method of treatment using it | UNITED STATES GOVERNMENT AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH AND HUMAN SERVICES (US) | 1990-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326725-A1 | PI4-Kinase Inhibitors and Methods of Using the Same | PI4KB, PI4KA, PI4K2A | AHCY 1340/4885EZH2 3432/4885AHCYL1 960/4885 |
| US-12466849-B2 | Anti-viral and anti-tumoral compounds | EIF2AK2, NSUN2, SARS1 | AHCY 3018/4885EZH2 463/4885AHCYL1 2373/4885 |
| US-12415788-B2 | PI4-kinase inhibitors and methods of using the same | PI4KB, PI4KA, PI4K2A | AHCY 1340/4885EZH2 3432/4885AHCYL1 960/4885 |
| US-12590288-B2 | Method of treating an inflammatory disease by administering an agent which binds a surface receptor on a tuft cell that induces an ILC class 2 inflammatory response | GPR3, GALR3, NR4A3 | AHCY 3973/4885EZH2 1721/4885AHCYL1 2763/4885 |
| US-20110237606-A1 | 3-Deazaneplanocin Derivatives | EZH2, SUZ12, DAZAP1 | AHCY 4001/4885EZH2 1/4885AHCYL1 3115/4885 |
| US-20150291640-A1 | PHOSPHONUCLEOSIDES USEFUL IN THE TREATMENT OF VIRAL DISORDERS | ENTPD5, PNP, MTAP | AHCY 4360/4885EZH2 2574/4885AHCYL1 4593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.